Bausch + Lomb announced July 10 that it would discontinue development of a neuroprotective eye drop candidate for glaucoma, citing Phase II results in which BL1107, a prodrug of brimonidine tartrate, failed to reach its primary visual field endpoint.

The company said it will, however, continue to develop BL1107 as a sustained-release implant for geographic atrophy, in cooperation with Ripple Therapeutics. Ripple’s technology aims to engineer drugs into controlled-release implants without the use of polymers. Trials are expected to begin in 2028.

Bausch + Lomb acquired BL1107, formerly WB007, in its deal for Whitecap Biosciences in 2025.

Bausch + Lomb, headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey, said its portfolio includes more than 60 assets under development, with several milestones expected in the next few months.

Study Results

The Phase II trial of BL1107 as an eye drop enrolled 159 adults with primary open-angle glaucoma or ocular hypertension. The study did not meet its primary endpoint, defined as change from baseline in visual field mean deviation at day 28.

Key secondary endpoints assessing visual function, including low-luminance best-corrected visual acuity responder rates, were also not achieved. The drug did, however, show a reduction in intraocular pressure at day 28.

More News

Want to Read Locked Articles?

Already Have an Account?

Register A Corporate Account

Topics of Interest

Products of Interest